title: Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients.
abstract: BACKGROUND
  The cytochrome P450 3A5 (CYP3A5) enzyme has been implicated to determine blood pressure (BP) in humans. Different results have been reported concerning CYP3A5 gene polymorphisms and posttransplantation hypertension in kidney recipients. Our objective was to investigate whether CYP3A5 1/3 polymorphism was associated with ambulatory BP among a population of renal transplant recipients receiving the calcineurin inhibitor tacrolimus for immunosuppression.
  
  
  METHODS
  Sixty primary kidney transplant recipients undergoing treatment with tacrolimus were genotyped for the CYP3A5 1/3 polymorphism. We analysed the association of the CYP3A5 alleles with ambulatory systolic and diastolic BP measured at 6 and 24 months posttransplantation.
  
  
  RESULTS
  We observed that 23.3% of the patients were CYP3A5 1 carriers and 76.7% were homozygous for CYP3A5 3. CYP3A5 1 carriers showed higher adjusted systolic BP and diastolic BP at 6 and 24 months posttransplantation, and they were prescribed more antihypertensive drugs compared with non CYP3A5 1 carrier patients, albeit not significant. No significant differences were found comparing the distribution of the hypertension classes.
  
  
  CONCLUSIONS
  We did not observe a significant association of CYP3A5 1/3 polymorphism with posttransplantation hypertension, although there were some differences in BP associated with the presence of the CYP3A5 1 allele.
authors.affiliation: Unidad Inmunología, C.H.U. Insular Materno Infantil, Las Palmas, Spain. atorruib@gobiernodecanarias.org
authors.forename: A
authors.initials: A
authors.lastname: Torio
authors.forename: I
authors.initials: I
authors.lastname: Auyanet
authors.forename: O
authors.initials: O
authors.lastname: Montes-Ares
authors.forename: R M
authors.initials: RM
authors.lastname: Guerra
authors.forename: E J
authors.initials: EJ
authors.lastname: Fernandez
authors.forename: M A
authors.initials: MA
authors.lastname: Perez
authors.forename: A
authors.initials: A
authors.lastname: Ramirez
authors.forename: M D
authors.initials: MD
authors.lastname: Checa
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D018660:Blood Pressure Monitoring, Ambulatory; D065095:Calcineurin Inhibitors; D051544:Cytochrome P-450 CYP3A / Q000235:genetics* / Q000378:metabolism; D005260:Female; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics* / Q000503:physiopathology; D007166:Immunosuppressive Agents / Q000378:metabolism / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011110:Polymorphism, Genetic; D016559:Tacrolimus / Q000378:metabolism / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; D016559:Tacrolimus